In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Hodgson

Data Editor, Pharma

Cambridge, U.K
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better.
Advertisement
Set Alert for Articles By John Hodgson

Latest From John Hodgson

Stock Scan April 2018: Pharma's Fizz Falls Flat

In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.

 

How To Grow A Drug - 2017 Top Sellers

What does a good drug launch look like? Is pharma getting better at them? Which drugs are likely still to be in the top 20 in five years' time? Get the picture with Scrip's interactive infographic.

 

Commercial Growth

Billion Dollar Bets, Health Care Magic

Investments of over $100 million are now close to becoming the predominant class of venture capital deployed in the life sciences. What is behind this shift in venture investing and how might it impact companies' strategy to attract the big bucks.

Financing Market Intelligence

Stock Scan Q1 2018: A Slump And A Proper Correction

The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.

Sales & Earnings Companies

STORM CEO Outlines Business Model And Pipeline Goals

Keith Blundy, CEO of STORM Therapeutics, discusses the companys founding and upcoming milestones.  

Business Strategies Commercial

Novo Holdings: Investing In Biopharma Growth

Stephan Christgau, a senior partner at Novo Holdings, talks about the firm’s approach to early-stage funding in biotech and how this financing arm aligns with Novo’s broader strategy.

StartUps and SMEs Commercial
See All
Advertisement
UsernamePublicRestriction

Register